FRONT PAGE STOCKS

[Trooperstocks]

$GDHG .288 +9.70% is dedicated to innovation and excellence. We're seeking new ways to enhance the visitor experience and drive sustainable growth. Our portfolio spans a range of attractions, from thrilling rides to family-friendly entertainment #amusementparks #profitable #investment @Nasdaq $GDHG $DIS $SIX $SEAS $CMCSA

GDHG is dedicated to innovation and excellence. We're seeking new ways to enhance the visitor experience and drive sustainable growth. Our portfolio spans a range of attractions, from thrilling rides to family-friendly entertainment #amusementparks #profitable #investment @Nasdaq pic.twitter.com/KUgv3r72ze

— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 19, 2024

[Trooperstocks]

$ASTI Configurable to mission power, mass, and delta-v budget requirements. The Sustainable Space Solar Solution. @Nasdaq @NASA @SpaceX https://investors.ascentsolar.com/overview/default.aspx @elonmusk

[Trooperstocks]

$GDHG Strong close .26 +20.37% HOD .2637 #bullish

[Trooperstocks]

$NRXP NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics & Royalty Rights on Ketamine Sales to Existing NRx Shareholders

Read More - https://ir.nrxpharma.com/2024-03-18-NRx-Pharmaceuticals-NASDAQ-NRXP-Announces-Plan-to-Distribute-Shares-of-HOPE-Therapeutics-and-Royalty-Rights-on-Ketamine-Sales-to-Existing-NRx-Shareholders

#PharmaNews #mentalillness #depression #ketamine #PTSD #bipolar #NRX100 #NRX101 $NRXP

[Trooperstocks]

$ASTI New Spacecraft Projects using Advanced Solar Technology; Partnership between Ascent Solar Technologies, Inc NASDAQ: ASTI @AscentSolar https://www.einpresswire.com/article/704169987/new-spacecraft-projects-using-advanced-solar-technology-partnership-between-ascent-solar-technologies-inc-nasdaq-asti via @ein_news @Nasdaq $MNTS $GDHG $NRXP $CLSK $TSLA

[Trooperstocks]

$NCL .495 +5.32% Northann Corp. (NYSE American: NCL) is thrilled to announce a groundbreaking partnership with i4F Patents & Technologies, marking a significant milestone in our journey towards revolutionizing the home improvement industry! https://globenewswire.com/news-release/2024/04/10/2860695/0/en/Northann-Corp-Announces-Cross-Licensing-Agreement-with-I4F-for-Digital-Printing-Technology.html

[Trooperstocks]

$ASTI and $MNTS Partnership Announced #Nasdaq
$ASTI Momentus and Ascent Solar Technologies Partner to Bring to Market Leading-Edge Solar Arrays
Wed, April 17, 2024
In this article: ASTI / MNTS
https://www.businesswire.com/news/home/20240417134583/en/

[Trooperstocks]

$RENB News: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
Renovaro Biosciences Inc.
Thu, April 18, 2024 at 8:45 AM EDT
In this article: RENB
+5.41%

LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.

Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.

Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.

Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.

As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.

“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”

Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”

With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.

About Renovaro:

Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: [e-mail]

Source: Renovaro Inc.

[Trooperstocks]

$GVH $1.30 +11.11% Globavend Nasdaq: GVH https://www.einpresswire.com/article/696719466/effortless-and-debt-free-e-commerce-logistics-provider-serving-the-lucrative-asia-pacific-market-globavend-nasdaq-gvh via @ein_news

[Trooperstocks]

$NRXP NEWS: @NRxPharma NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-receives-123200514.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
@YahooFinance

[Trooperstocks]

$GDHG - Recent Press Releases on http://Nasdaq.com https://nasdaq.com/market-activity/stocks/gdhg/press-releases
For more information on us, please visit our official company website https://ir.jsyoule.com #Nasdaqlisted
#amusementpark #china $DIS $SIX

GDHG - Our Recent Press Releases on https://t.co/ib98sBbzcZ https://t.co/fiWKs8hDOX
For more information on us, please visit our official company website https://t.co/o6KKIHgysk #Nasdaqlisted pic.twitter.com/Rha8YNr7oD

— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 18, 2024

[Trooperstocks]

$AVRW New and Perfect Skincare Product, Seratopical Solutions' "Harmony Toner", is Now Available on the Seratopical Website!
Great video with Facial Plastic Surgeon Dr. Michael Persky
Link: https://seralabshealth.com/products/
#sales #revenues $JNJ $CVS $AMZN

[Trooperstocks]

$NCL Northann Corp.’s New 3-D Printing Ecosystem Products Receive “Best of” Innovation Awards at TISE2024
https://axecapitalusa.com/ncl/

[Trooperstocks]

$GDHG Only 27% Of Chinese Citizens Have Visited Amusement Parks, And Demand Is Now Growing – Golden Heaven (NASDAQ: GDHG) Plans To Ride The Wave $GDHG https://www.benzinga.com/partner/emerging-markets/24/04/38181116/only-27-of-chinese-citizens-have-visited-amusement-parks-and-demand-is-now-growing-golde via @Benzinga

[Trooperstocks]

$GVH Globavend Holdings - CEO Wai Yiu Yau, "This equity line facility provides Globavend with a viable long-term platform to grow its existing operations, expand its e-commerce logistics services into different verticals of the logistics supply chain."
https://www.wsj.com/articles/globavend-holdings-limited-enters-into-a-us-20-000-000-equity-line-of-credit-facility-to-be-registered-on-form-f-1-44a21f4f?reflink=mw_share_twitter

[Trooperstocks]

$ASTI Ascent Solar Technologies, (Nasdaq("Ascent": $ASTI) and Momentus Inc. (NASDAQ: $MNTS) ("Momentus") Partner to Bring Leading-Edge Solar Arrays to Market
@AscentSolar
#Momentus https://marketwatch.com/press-release/momentus-and-ascent-solar-technologies-partner-to-bring-leading-edge-solar-arrays-to-market-b8c1bd1d?mod=mw_quote_news_seemore

[Trooperstocks]

GREAT POST BY GOLDEN HEAVEN GROUP @Nasdaq! $GDHG - Our amusement parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals and theatrical shows.
https://ir.jsyoule.com/companyinformation.html?type=company
@Nasdaq
#China #AmusementParks $DIS $SEAS $SIX

$GDHG - Our amusement parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals and theatrical shows.https://t.co/zTVx94FDB6 @Nasdaq #China #AmusementParks $DIS $SEAS $SIX pic.twitter.com/HrE2W6EMHm

— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 17, 2024

[Trooperstocks]

$ASTI News: Momentus and Ascent Solar Technologies Partner to Bring to Market Leading-Edge Solar Arrays
Wed, April 17, 2024 at 10:00 AM EDT
In this article: ASTI / MNTS

Innovative solar arrays to address burgeoning need

SAN JOSE, Calif., April 17, 2024--(BUSINESS WIRE)--Momentus Inc. (NASDAQ: MNTS) ("Momentus") and Ascent Solar Technologies (Nasdaq: ASTI) ("ASTI") today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules.

The rapid growth in the production and deployment of thousands of satellites in space has led to the burgeoning need for low-cost, reliable solar arrays with high performance. Momentus and Ascent are excited to partner to market a leading-edge solar array designed to provide key advantages to customers, such as low-cost, resiliency with less degradation in the harsh environment in space, flexibility, and the ability to efficiently generate large amounts of power.

Building off the successes of the pathfinder demonstration of TASSA that was launched to Low-Earth Orbit on the Vigoride-6 mission one year ago and tested in space for several months, Momentus plans to add a high-power photovoltaic array as a differentiated feature of the next iteration of the TASSA product under development. Last year’s pathfinder TASSA demonstration validated solar blankets from Ascent Solar Technologies (Nasdaq: ASTI) ("ASTI") as a mass efficient and robust power generation solution. Momentus plans to incorporate in TASSA new higher efficiency solar blankets from ASTI composed of space industry optimized Titan Modules, providing even lower cost per kW of power.

TASSA will continue to utilize Vigoride hardware with spaceflight heritage to provide customers an entire array subsystem complete with solar array rotation actuators and controllers. This approach is oriented at streamlining mission schedules and minimizing clean room bottlenecks during spacecraft assembly integration and testing. TASSA is designed for responsive launch as well as more efficient flatpack configurations which allow for more satellites to fit within launch vehicle payload fairings.

"TASSA is designed to generate extensive power at very low cost while minimizing mass and volume," said Rob Schwarz, Momentus CTO. "TASSA is intended to allow Smallsats to generate kilowatts of power on orbit without breaking their mass, thermal, or cost budgets. This design optimization also facilitates improved satellite packing efficiencies and allows constellations to be fielded quicker and cheaper."

TASSA is also retractable and re-deployable, providing a means for the minimization of cross-sectional area and array exposure if notified of potential conjunction or other orbital hazards such as space weather. This could enable TASSA to facilitate longer mission durations and increased assurance of spacecraft operations on orbit.

"Ascent’s flexible, lightweight photovoltaic modules are ideal for the space environment," says Paul Warley, ASTI CEO, "as our CIGS products are resilient to radiation and other drivers of degradation while operating in orbits between the Earth and the Moon. For those designing space missions, this equates to more end-of-life power with an order of magnitude less mass. We’re excited to be the baseline power generation solution for TASSA and look forward to continuing to collaborate with the Momentus team to provide long-lived and sustainable solutions for proliferated space architectures."

ABOUT MOMENTUS

Momentus is a U.S. commercial space company that offers satellite buses and technologies, as well as space services including transportation, hosted payloads, and other in-orbit services.

ABOUT ASCENT SOLAR TECHNOLOGIES, INC.

Backed by 40 years of R&D, 15 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio, Ascent Solar Technologies, Inc. is a leading provider of innovative, high-performance, flexible thin-film solar panels for use in environments where mass, performance, reliability, and resilience matter. Ascent’s photovoltaic (PV) modules have been deployed on space missions, multiple airborne vehicles, agrivoltaic installations, in industrial/commercial construction as well as an extensive range of consumer goods, revolutionizing the use cases and environments for solar power. Ascent Solar’s research and development center and 5-MW nameplate production facility is in Thornton, Colorado. To learn more, visit https://www.ascentsolar.com or follow the Company on LinkedIn and X (formerly Twitter).

Forward-Looking Statements

This press release contains certain statements which may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding Momentus or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. The words "may," "will," "anticipate," "believe," "expect," "continue," "could," "estimate," "future," "expect," "intends," "may," "might," "plan," "possible," "potential," "aim," "strive," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus’ control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: the ability of the Company to generate revenue and raise capital in order to continue as a going concern; the ability of the Company to obtain licenses and government approvals for its missions, which are essential to its operations; the ability of the Company to effectively market and sell satellite transport services and planned in-orbit services; the ability of the Company to protect its intellectual property and trade secrets; the development of markets for satellite transport and in-orbit services; the ability of the Company to develop, test and validate its technology, including its water plasma propulsion technology; delays or impediments that the Company may face in the development, manufacture and deployment of next generation satellite transport systems; the ability of the Company to convert backlog or inbound inquiries into revenue; changes in applicable laws or regulations and extensive and evolving government regulations that impact operations and business, including export control license requirements; the ability to attract or maintain a qualified workforce with the required security clearances and requisite skills; product service or product or launch failures or delays that could lead customers to use competitors’ services; investigations, claims, disputes, enforcement actions, litigation and/or other regulatory or legal proceedings; the Company’s ability to comply with the terms of its National Security Agreement and any related compliance measures instituted by the director who was approved by the CFIUS Monitoring Agencies; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and/or other risks and uncertainties. These are only some of the factors that may affect the forward-looking statements contained in this press release. For a discussion identifying additional important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, see the company’s filings with the U.S. Securities and Exchange Commission including, but not limited to, "Management’s Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The Company’s filings may be accessed through the Investor Relations page of its website, investors.momentus.space, or through the website maintained by the SEC at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240417134583/en/

Contacts

Media: [e-mail]
Investors: [e-mail]

[Trooperstocks]

$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
Wed, April 17, 2024 at 8:30 AM EDT
In this article: NRXP

New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections

NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine

NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis

RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.

C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.

D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.

Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.

"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.

About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)

Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.

Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.

NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html

SOURCE NRx Pharmaceuticals, Inc.

[Trooperstocks]

$NCL News: Northann Corp.'s Benchwick Brand to Showcase SuperOak Hybrid Wood Planks Alongside Blue11 Collection at NWFA in New Orleans, April 16-18, 2024 https://finance.yahoo.com/news/northann-corp-benchwick-brand-showcase-120000189.html

[Trooperstocks]

$NRXP Great news for @NRxPharma as @ZacksResearch upgrade to a Strong BUY! https://www.zacks.com/stock/quote/NRXP

[Trooperstocks]

$AVRW #OTCQB Avenir Wellness Solutions Issued a Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky

New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales

https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html

[Trooperstocks]

$GDHG - Only 27% Of Chinese Citizens Have Visited Amusement Parks, And Demand Is Now Growing – Golden Heaven (NASDAQ: GDHG) Plans To Ride The Wave and Appears to be benefitting from this trend. https://newsdirect.com/news/only-27-of-chinese-citizens-have-visited-amusement-parks-and-demand-is-now-growing-golden-heaven-nasdaq-gdhg-plans-to-ride-the-wave-801148041 @newsdirect #Nasdaq

$TSLA $AAPL $DIS $SIX $SEAS

[Trooperstocks]

$NCL Northann Corp. inks cross-licensing agreement with I4F who provides patents and technologies to the flooring industry. #DD
@Nasdaq
Northann inks cross-licensing agreement with I4F who provides patents and technologies to the flooring industry.
$MSFT $AMD $NVDA $GVH
https://www.benzinga.com/markets/equities/24/04/38184285/printing-the-future-northann-and-i4f-forge-cross-license-deal

[Trooperstocks]

$ASTI Ascent Solar Technologies Achieves CIGS Technology Power Generation Milestones at Production Scale with Thin Film #MarketScreener https://www.marketscreener.com/quote/stock/ASCENT-SOLAR-TECHNOLOGIES-111313590/news/Ascent-Solar-Technologies-Achieves-CIGS-Technology-Power-Generation-Milestones-at-Production-Scale-w-46277238/?utm_source=twitter&utm_medium=social&utm_campaign=share $AMBA $CGNX $DUOT $EXAS $FSLR $GFAI $QCOM $RTX $ST $S $SOUN $STEM $TTD $PATH

[Trooperstocks]

$IVDN: Our patented Insultex House Wrap (TM) meets or exceeds new building codes taking effect in 2024 that require continuous insulation for greater energy efficiency. It provides an unmatched R-6 Rating via a unique evacuated cell design. Visit: http://insultexhousewrap.com

$IVDN: Our patented Insultex House Wrap (TM) meets or exceeds new building codes taking effect in 2024 that require continuous insulation for greater energy efficiency. It provides an unmatched R-6 Rating via a unique evacuated cell design. Visit: https://t.co/LWNDwJcXDh https://t.co/ovQzzaFfkv pic.twitter.com/OzMJYqx9uz

— Innovative Designs, Inc (Stock: $IVDN) (@riccelli_joseph) April 4, 2024

[mcnierney1]

IBGR The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 71.19% during the next 3 months and, with a 90% probability hold a price between $0.0120 and $0.0253 at the end of this 3-month period.
Bullish
BULLISH

[Trooperstocks]

$ASTI Ascent Solar Technologies Announces Substantial Debt Reduction and Plan for Full Payoff
Globe Newswire

THORNTON, Colo., March 21, 2024 (GLOBE NEWSWIRE) -- Ascent Solar Technologies, Inc. ("Ascent," or the "Company") (NASDAQ:ASTI) https://marketchameleon.com/PressReleases/i/1865010/ASTI/ascent-solar-technologies-announces-substantial-debt-reducti $SBFM $SNPW $PATH

[Trooperstocks]

$GVH Globavend , NeoVolta, Ceasarstone among industrial movers. $NEOV $NVX $CETY $FLUX https://marketchameleon.com/Financial-News/NKLA/15502010/4088991-globavend-neovolta-caesarstone-among-industrial-movers?utm_source=marketchameleon.com&utm_medium=referral&feed_item_type=news

[Trooperstocks]

$NRXP NRX Pharmaceuticals's short percent of float has risen 987.89% since its last report. The company recently reported that it has 4.25 million shares sold short, which is 62.88% of all regular shares that are available for trading. https://www.benzinga.com/insights/short-sellers/24/04/38249539/nrxp-analyzing-nrx-pharmaceuticalss-short-interest via @Benzinga

[deri21]

$BLQC BlockQuarry Corp. Annual Report
https://www.otcmarkets.com/otcapi/company/financial-report/397691/content

[Trooperstocks]

$NCL @Northann_Corp Northann Corp Announces Cross-Licensing Agreement with I4F for Digital Printing Technology https://finance.yahoo.com/news/northann-corp-announces-cross-licensing-120000885.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance $KAVL $LGVN $HUBC $YYAI $KUKE $SPCB $RZLT $INDO $MXC $IZM $ONVO $SNPO

[budfoxfun]

$NBIO huge news today! April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial.

"Taking the time to navigate this opportunity with proper care and diligence is a step that demonstrates our commitment to the best interests of our investors, partners, shareholders, and potential future patients," remarked Sean Carrick, CEO of NBIO. "No one likes delays, but patience and care at this critical stage is necessary in maximizing patient outcomes and long-term shareholder value. We want to be careful not to make hasty decisions while exploring all options.

This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Glioblastoma. 12 of 15 patients had this diagnosis.

There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study.

[Trooperstocks]

$GDHG - The global theme park market is a behemoth, projected to reach a staggering US 87.69 billion by 2031, with a Compound Annual Growth Rate exceeding 4.1%. Asia Pacific is The dominant player, driven by rapid economic growth and a growing middle class, particularly in China. #amusementpark #growthrate

$GDHG - The global theme park market is a behemoth, projected to reach a staggering US 87.69 billion by 2031, with a Compound Annual Growth Rate exceeding 4.1%. Asia Pacific is The dominant player, driven by rapid economic growth and a growing middle class, particularly in China. pic.twitter.com/G03nMaBuO2

— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 16, 2024

[Trooperstocks]

$GDHG - Positive Valuation via LSEG Data & Analytics Stock Report Plus for April 14, 2024
@Nasdaq

Despite market challenges, GDHG maintained robust financials in fiscal year 2023, with a total revenue of $31.8 million and a net income of $6.5 million. #amusementparks

[Trooperstocks]

$IVDN #OTCQB -Innovative Designs Vendor Growth https://www.wsj.com/articles/innovative-designs-vendor-growth-14d71d70?reflink=mw_share_twitter $MSFT $NCL $PATH

[Trooperstocks]

$NRXP @NRxPharma NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy https://www.zacks.com/stock/news/2250692/nrx-pharmaceuticals-nrxp-upgraded-to-strong-buy-heres-what-you-should-know?art_rec=quote-stock_overview-zacks_news-ID01-txt-2250692 $BMY $PFE $JNJ

[Trooperstocks]

$AVRW Great Video here: CEO Nancy Duitch and Brand Ambassador Nicole Kidman Discuss their Alliance to Support Wholly-Owned Subsidiary Sera Labs
https://vid.cdn-website.com/ad0e02d3/videos/uJEcyoV4QPmJKpXoSxbh_Untitled-v.mp4

[Bansky]

$EBYH

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.otcmarkets.com/otcapi/company/dns/news/document/73922/content

NEW YORK, April 15, 2024 (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH)
Strainsforpains, Inc. is pleased to announce that it has released its annual report, showing
increased sales of 1000% from $7400 in 2022 to $84,000 in 2023. The company has announced that its
first quarter 2024 has seen a $130,000 order for its CBD products as well.
Mr. Shainberg, Strainsforpains president stated that “We anticipate 2024 to be a milestone year for
us, not just with major increases in revenues, but also joint ventures in developments of new
products, licensing agreements, upgrade to our pain management app utilizing the latest in
artificial intelligence, and the finalization of our seven acre Pennsylvania facility renovations
for manufacturing and distribution of CBD products”.
The company is working with scientists and doctors well known in their fields, in areas of water
solubility of CBD, as well as new anti-inflammatory additives to our CBD products. We have entered
into a licensing deal with GenBio, primarily a US-based biotech research Company, and its mission
is to develop the next generation of anti-inflammatory drugs.
Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its
upcoming audited financials within 2024.

[Trooperstocks]

$ASTI Thin Film Solar Power Technology Used in Aerospace & Consumer Goods; Reaching Record-Breaking Milestones: NASDAQ: ASTI https://einpresswire.com/article/702626332/thin-film-solar-power-technology-used-in-aerospace-consumer-goods-reaching-record-breaking-milestones-nasdaq-asti

[FinlayS00]

$IQST - iQSTEL $1 billion revenue on the horizon! QXTEL deal adds $80M sales!
https://marketsherald.com/iqstel-inc-s-accelerated-path-to-1-billion-a-study-in-strategic-growth/

[Trooperstocks]

$GDHG Currently Managing Six Properties Consisting of Amusement Parks, Water Parks, Gourmet Festivals, Circus Performances and High-Tech Facilities. https://southeast.newschannelnebraska.com/story/50537986/new-amusement-park-attendance-record-set-preceding-major-expansion-into-indonesia-with-30-50-new-park-openings-plus-6-million-share-repurchase-plan #wsj #nytimes #business #reuters #IHub #forbes #marketwatch #Benzinga $HUBC $SPCB $LVGN $ALLR $SNPO $PLL

[Trooperstocks]

$NRXP @Nasdaq Buy any Dips. @NRxPharma NRX's (NASDAQ: $NRXP) NMDA Modification Therapy And Its Multiple Applications From Mental Health To Chronic Pain @Benzinga
https://benzinga.com/partner/biotech/24/04/38180971/nrxs-nasdaq-nrxp-nmda-modification-therapy-and-its-multiple-applications-from-mental-health-to-ch #PharmaNews #mentalillness #mentalhealth #depression #ketamine #NRX100 #NRX101 $GVH $JNJ

[Trooperstocks]

$GVH Experienced, Well Partnered, Effortless and Debt Free e-Commerce Logistics Provider Serving the Lucrative Asia- Pacific Market: Globavend Holdings Limited (Nasdaq: GVH) $MSFT $AMD @Nasdaq https://www.benzinga.com/pressreleases/24/03/ab37795054/experienced-well-partnered-effortless-and-debt-free-e-commerce-logistics-provider-serving-the-luc via @Benzinga

[Trooperstocks]

$NCL PREMARKET $0.52 +4.00% Apr 15, 2024

Printing The Future: Northann Corp. And I4F Forge Cross-License Deal $MSFT $AMD $NVDA $GVH https://www.benzinga.com/markets/equities/24/04/38184285/printing-the-future-northann-and-i4f-forge-cross-license-deal via Benzinga

[Trooperstocks]

$ASTI Ascent Solar Technologies Achieves CIGS Technology Power Generation Milestones at Production Scale with Thin Film #MarketScreener https://www.marketscreener.com/quote/stock/ASCENT-SOLAR-TECHNOLOGIES-111313590/news/Ascent-Solar-Technologies-Achieves-CIGS-Technology-Power-Generation-Milestones-at-Production-Scale-w-46277238/?utm_source=twitter&utm_medium=social&utm_campaign=share $AMBA $CGNX $DUOT $EXAS $FSLR $GFAI $QCOM $RTX $ST $S $SOUN $STEM $TTD $PATH

[FinlayS00]

$IQST is one of the best stocks to buy now in April 2024!

[Trooperstocks]

$ASTI Configurable to mission power, mass, and delta-v budget requirements. The Sustainable Space Solar Solution. @Nasdaq @NASA @SpaceX https://investors.ascentsolar.com/overview/default.aspx @elonmusk

[Trooperstocks]

$GDHG - Tongling West Lake Amusement World is stationed in the prosperous area of ??Xihu Avenue, Tongguan District, Tongling City, Anhui Province has the most popular large-scale amusement equipment such as high-altitude flying and reciprocating roller coasters in China. @Nasdaq #amusementparks #equipment #rollercoasters $DIS $SIX $CMCSA $GDHG

$GDHG - Tongling West Lake Amusement World is stationed in the prosperous area of ​​Xihu Avenue, Tongguan District, Tongling City, Anhui Province has the most popular large-scale amusement equipment such as high-altitude flying and reciprocating roller coasters in China. @Nasdaq pic.twitter.com/Z87HpFjVYg

— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 12, 2024

[Trooperstocks]

$AVRW Security Details #OTCQB https://www.otcmarkets.com/stock/AVRW/security